Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T11:56:09.710Z.
Calculation as of: 2026-10-06T11:56:09.710Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0793561984d12013d5f07d0ccc5da74adc08ebcd6005adbeade30d207b80f537
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$84.75M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$81.22M
EV/FCF Ratio
N/A
TTM Avg
816.68x
3Y Avg
816.68x
5Y Avg
816.68x
Market Cap
$87.86M
EV/FCF Ratio
N/A
TTM Avg
17.26x
3Y Avg
15.52x
5Y Avg
17.05x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cognition Therapeutics, Inc. (CGTX) | $83.96M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 5.87x | 5.69x | 5.19x | 9.05x |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | N/A | 816.68x | 816.68x | 816.68x |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | N/A | 17.26x | 15.52x | 17.05x |
| electroCore, Inc. (ECOR)vs › | $91.33M | N/A | N/A | N/A | N/A |
| Equillium, Inc. (EQ)vs › | $91.68M | N/A | 5.17x | 5.17x | 5.17x |
| Biomea Fusion, Inc. (BMEA)vs › | $93.99M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
